Keros Therapeutics (KROS) News Today $13.09 +0.35 (+2.75%) Closing price 04:00 PM EasternExtended Trading$12.88 -0.21 (-1.63%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Adar1 Capital Management, Llc Acquires 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) StockApril 15 at 4:10 AM | insidertrades.comFederated Hermes Inc. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Federated Hermes Inc. purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 124,620 shares of the company's stock, valued at approximately $1,973,000. FederaApril 15 at 3:58 AM | marketbeat.comNorges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Norges Bank acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 64,900 shares of the company's stock, valued at approximately $1,02April 14 at 3:29 AM | marketbeat.comKeros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors purchased 4,215 put options on the company. This is an increase of 287% compared to the average daily volume of 1,090 put options.April 13 at 11:37 AM | marketbeat.comKeros Therapeutics Sees Unusually Large Options Volume (NASDAQ:KROS)April 13 at 1:24 AM | americanbankingnews.comKeros Therapeutics: Strategic Alternatives Could Bring About Value CreationApril 11, 2025 | seekingalpha.comTruist Financial Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock PriceTruist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday.April 11, 2025 | marketbeat.comKeros reviewing strategic alternatives, adopts shareholder rights planApril 10, 2025 | markets.businessinsider.comKeros Therapeutics, Inc.: Keros Therapeutics Announces Review of Strategic AlternativesApril 10, 2025 | finanznachrichten.deKeros Therapeutics stock jumps on strategic review, potential saleApril 10, 2025 | investing.comKeros Therapeutics price target lowered to $25 from $43 at TruistApril 10, 2025 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Keros Therapeutics (KROS)April 10, 2025 | markets.businessinsider.comKeros climbs after strategic review; adopts poison pillApril 10, 2025 | msn.comKeros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s OverjoyedApril 10, 2025 | msn.comKeros Therapeutics adopts 'poison pill' planApril 10, 2025 | reuters.comKeros Therapeutics adopts 'poison pill' planApril 10, 2025 | reuters.comKeros Therapeutics Announces Review of Strategic AlternativesApril 10, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by ADAR1 Capital Management LLCADAR1 Capital Management LLC trimmed its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 94.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,246 shareApril 9, 2025 | marketbeat.comBryce Point Capital LLC Invests $445,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)Bryce Point Capital LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,127 shares of the company's stock, valued at approximately $April 7, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases 31,251 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)American Century Companies Inc. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,920 shares of the company'sApril 6, 2025 | marketbeat.comClearbridge Investments LLC Invests $3.01 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Clearbridge Investments LLC acquired a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 190,064 shares of the company's stockApril 5, 2025 | marketbeat.comWedbush Reiterates Neutral Rating for Keros Therapeutics (NASDAQ:KROS)Wedbush reiterated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Tuesday.April 2, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Keros Therapeutics (NASDAQ:KROS)HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research note on Tuesday.April 2, 2025 | marketbeat.com2KROS : Forecasting The Future: 7 Analyst Projections For Keros TherapeuticsApril 1, 2025 | benzinga.comKeros Therapeutics reports results from Phase 1 clinical trial of KER-065March 31, 2025 | markets.businessinsider.comKeros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy VolunteersMarch 31, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the cMarch 29, 2025 | marketbeat.comEmerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Advisers LLC raised its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 57.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,633 shares of the company's stock afterMarch 25, 2025 | marketbeat.com29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,146 shares of tMarch 23, 2025 | marketbeat.comKeros Therapeutics: Losing Its Lead Drug Is Bad MedicineMarch 13, 2025 | seekingalpha.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from AnalystsKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to theMarch 3, 2025 | marketbeat.comFY2026 EPS Estimate for Keros Therapeutics Lifted by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Keros Therapeutics in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now anticipates that the comMarch 3, 2025 | marketbeat.comWhat is William Blair's Forecast for KROS Q1 Earnings?Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of Keros Therapeutics in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps forecasts that the comMarch 3, 2025 | marketbeat.comQ1 EPS Forecast for Keros Therapeutics Lifted by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Keros Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($March 3, 2025 | marketbeat.comBank of America Securities Remains a Buy on Keros Therapeutics (KROS)March 2, 2025 | markets.businessinsider.comQ2 Earnings Estimate for KROS Issued By Leerink PartnrsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the compMarch 1, 2025 | marketbeat.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesFebruary 28, 2025 | globenewswire.comWells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock PriceWells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday.February 28, 2025 | marketbeat.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00HC Wainwright dropped their price target on Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday.February 28, 2025 | marketbeat.comKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 | finanznachrichten.deWells Fargo Sticks to Their Buy Rating for Keros Therapeutics (KROS)February 27, 2025 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Beats Expectations By $0.22 EPSKeros Therapeutics (NASDAQ:KROS - Get Free Report) posted its earnings results on Wednesday. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.February 27, 2025 | marketbeat.comY Intercept Hong Kong Ltd Boosts Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Y Intercept Hong Kong Ltd raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,910.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,255 shares of the company's stock afteFebruary 27, 2025 | marketbeat.comTD Cowen Remains a Hold on Keros Therapeutics (KROS)February 26, 2025 | markets.businessinsider.comKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | globenewswire.comKeros Therapeutics (KROS) to Release Quarterly Earnings on WednesdayKeros Therapeutics (NASDAQ:KROS) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest UpdateKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 4,260,000 shares, an increase of 6.0% from the January 15th total of 4,020,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is currently 2.8 days.February 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSFebruary 11, 2025 | prnewswire.comLeerink Partnrs Has Bullish Outlook for KROS FY2028 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2028 earnings per share estimates for shares of Keros Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the cFebruary 10, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy ratingFebruary 6, 2025 | marketbeat.com Remove Ads Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.520.80▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼225▲KROS Articles Average Week Remove Ads Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mirum Pharmaceuticals News Belite Bio News Denali Therapeutics News Recursion Pharmaceuticals News Biohaven News Bausch Health Companies News Tarsus Pharmaceuticals News NewAmsterdam Pharma News Harmony Biosciences News Ascentage Pharma Group International News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts